INTRODUCTION
Becker muscular dystrophy (BMD, OMIM 300376) is an X-linked recessive form of muscular dystrophy caused by mutations in the dystrophin gene (DMD), which is located on chromosome Xp21.2. [1] The DMD gene is the largest gene identified in humans and contains 79 exons. Mutations in the gene result in a deficient dystrophin protein. [2] BMD is typically associated with mutations that maintain the open reading frame, producing an internally altered but partially functional dystrophin protein, with an intact C terminal domain. [3, 4] Patients with BMD have variable phenotypes, but are less severely affected than those with Duchenne muscular dystrophy (DMD), and have a much longer normal life expectancy. [4] Little is known about social and mental problems that accompany BMD. In a previous study, we found that BMD patients often experienced mental problems and difficulties in daily life (e.g., bullying) when they were attending school. Some patients also experienced mental stress at the workplace, which can lead to depression and neurosis. [5] However, we were unable to clarify the prevalence of psychotic disorders, difficulties in daily life, and other related factors among patients with BMD. This study aimed to clarify the prevalence not only of psychotic disorders but also of neurodevelopmental disorders and problematic behaviors, in addition to analyzing related factors among patients with BMD.
METHODS

Aim and design
This study aimed to clarify the prevalence not only of psychotic disorders but also of neurodevelopmental disorders and problematic behavior, as well as analyze related factors in patients with BMD. We also assessed whether these disorders and/or problematic behaviors correlate with the genotype of patients with BMD.
Participants
This study was approved by the Ethics Committee of the National Center of Neurology and Psychiatry (NCNP). We enlisted male patients with dystrophinopathy who visited the National Center Hospital of NCNP from July 1979 to September 2016. Among these patients, those with BMD aged ≥ 17 years were selected for this study. Patients who were ambulant at age 17 were defined as having BMD. [6] Interview A neurologist (MMY) requested genetically-or immunohistochemically-confirmed BMD patients to participate in the study interview. Interview items included: 1) age at onset, first symptoms, past and present ambulatory performance, and wheelchair use, 2) information about developmental disorders (e.g., mental retardation, autism, Asperger syndrome, attention deficit hyperactivity disorder, epilepsy, and others), 3) information about bullying and problematic behavior (e.g., cutting class, domestic violence, suicide attempts and/or self-mutilation, and violent incidents), and 4) information about the history of psychiatric diseases and diagnoses. Ambulation status was also evaluated during the interview.
Since we assessed disease onset after participants became symptomatic, we asked about the age of onset when any symptoms arose, rather than the age at which test abnormalities were found.
These interview reports were compared to medical records when there was a discrepancy between physical examination results and patient statements during the interview. We also collected information regarding history of psychiatric diseases from medical records.
Psychiatric and neurodevelopmental tests
Participants who consented to undergo psychiatric tests were assessed for intelligence (Wechsler 
Genetic diagnosis
Information regarding genetic diagnosis was collected from medical records. We divided participants into two groups according to mutations that might alter Dp140 expression, with the aim to verify a possible association between the loss of Dp140 and developmental, social, or psychiatric problems in BMD patients. Specifically, deletion/duplication/small mutations in the region between the Dp140 promoter and the N-terminus, and frameshift/nonsense mutations involving intron 44 or downstream, were assumed to be Dp140 expression modifiers. Among these possible modifiers, we defined deleterious Dp140 mutations as deletion mutations which include the Dp140 start codon and/or coding region, or coding region nonsense or splice site variants, and discriminated these from other mutations (potentially deleterious: deletion mutations which include the Dp140 promoter and exon 1 of Dp140, partial deletion within 5'UTR which may influence Dp140 expression, No: mutations that did not affect Dp140 expression). We also defined deleterious Dp71 mutations as deletion mutations 13 which include the Dp71 start codon and/or coding region, or coding region nonsense or splice site variants.
Radiological findings
MR examinations had been performed in 14 patients with BMD for the following reasons: incidental complications (falling, risk of cardiac embolism, tremor, deafness, amnesia, and loss of consciousness) in 6, no complication or psychological abnormalities but for a brain evaluation related to BMD in 4, severe psychiatric or developmental disorders (depression, schizophrenia, and/or mental retardation) in 3, and unknown in 1. Of these 14 participants, 9 had psychiatric diseases (schizophrenia, 4; depression, 2; neurosis, 2; bipolar disorder, 1), 4 had mental retardation, and 1 had pervasive development disorder. Two neuroradiologists (N.S. and E.M. with 20 and 14 years of experience in neuroradiology, respectively) independently assessed brain atrophy (severity, diffuse or focal, and location) and signal abnormalities on T1-weighted, T2-weighted and FLAIR images. Differences in evaluations were resolved by consensus. We also evaluated the relationships between these MR imaging and psychological findings.
Data analysis
Data are presented as mean ± standard deviation (SD), median, range, frequency, or percentage, as 14 indicated. The one-sample or two-sample t-test was used for continuous data and Fisher's exact test for binary data. Pearson's correlation coefficients were estimated to evaluate the relationships between continuous variables. Logistic regression models were applied using developmental disorders and psychiatric diseases as the outcome variables and age at onset, ambulation, WAIS-III FIQ, JART, and deleterious Dp140 mutations as the explanation variables. Missing data were multiply imputed using the fully conditional specification (FCS) method [7, 8] .
All statistical analyses were performed using SPSS for Macintosh (Version 24; SPSS Inc., Chicago, IL) and SAS (version 9.4; SAS Institute Japan, Tokyo).
RESULTS
Participant characteristics at study entry (Figure 1)
At the end of September 2016, a total of 104 BMD patients who fulfilled the inclusion criteria were considered candidates. Among them, 76 (74.1%) participated in this study. Mean age was 38.8 +/-13.3 (17-72, median 38), and mean age at BMD onset was 12.7 years; 73 were symptomatic and 3 were asymptomatic; 59 (77.6%) were ambulant, while 17 (22.4%) were not; and mean age at loss of ambulation was 33.9 years. None of the patients started steroids at age <17.
Developmental disorders, bullying, problematic behavior, and psychiatric diseases (Table 1) Six participants were diagnosed with developmental disorders (mental retardation, 5; pervasive developmental disorders, 1). One had severe mental retardation. Five patients had epilepsy, and 2 had febrile seizures.
Up until graduation, 57 (45.6%) participants experienced bullying, 11 exhibited problematic behavior such as cutting class (n=8) and domestic violence (n=3), and 16 were diagnosed with psychiatric diseases. There were 5, 5, 3, and 1 participants with schizophrenia, neurosis, depression, and bipolar disorder, respectively. Among those with neurosis, 1, 1, 1, and 2 participants had panic disorder, obsessive-compulsive disorder, adjustment disorder, and an unknown disorder, respectively.
One participant with neurosis also had depression.
Fisher's exact test revealed that developmental disorders (p=0.04) and problematic behavior (p=0.05) were significantly (p = 0.03) correlated with psychiatric diseases.
Intelligence and Psychological Tests (Tables 2 and 3, Figure 2)
Results of the psychiatric tests are shown in Table 2 and Figure 2 . The results of intelligence tests indicated that, on average, results were within the normal range (WAIS-III FIQ: 94.2±18.9, n=33, 50-138); JART: 105.1±9.9, n=45, 71.78-121.50), whereas 12.1% of participants were in the abnormal range. JART scores were significantly higher than WAIS-III FIQ (p=0.004) and PIQ (p=0.003) scores, but not significantly higher than the WAIS-III VIQ scores (p=0.073). One participant with severe mental retardation did not undergo the intelligence tests. PIQ was lower than VIQ, but not significantly (p=0.211). None of the participants had obvious hand weakness that would render writing or other test performance activity difficult.
Thirteen participants (32.5%) were deemed by the CES-D to be in a depressive state, although only 2 had been diagnosed with depression. Fifteen (38.5%) participants were in an anxious state, and 20 (50%) had high trait anxiety as noted by STAI.
The prevalence of disorders in 40 participants, as assessed by MINI, are shown in Table 3 .
Nineteen participants (25% of all participants, 46% of those assessed by MINI) met criteria for at least one lifetime MINI disorder (mood disorder, 8; anxiety disorder, 5; psychotic disorder, 2; substance use disorder, 2). Ten participants reported having attempted suicide. When MINI was used to rate current suicide risk, six participants were at one median risk, and 14 were at low risk.
Abnormalities of AQ, CAARS index in self-report and observer-report, and PARS for childhood and adolescence were 4 (11.4%), 8 (22.9%) and 3 (12.5%), and 3 (17.6%) and 0 (10.0%), respectively.
Relationship among clinical factors, developmental disorders, and psychological diseases
Logistic regression models revealed that none of the items were significant when the outcome variable was developmental disorders, but the JART score was found to be significantly associated with the existence of psychiatric diseases (odds ratio: 0.92, p=0.0143). As the confidence intervals for the two variables were extremely wide due to the small sample size, these variables were excluded from the model for sensitivity analysis. The significance of the included two variables in the sensitivity analysis did not change (p>0.7 for both).
Radiological abnormalities (Figure 3)
Previous MRI data of 14 participants were reviewed. Of the 14 participants, 10 had psychiatric diseases and/or developmental disorders. Nine participants had psychiatric diseases (schizophrenia, 4; depression, 2; neurosis, 2; bipolar disorder, 1), 4 had mental retardation, and 1 had pervasive development disorder. 
Quality of life and related indices (Table 4)
We obtained SF-36 national standard scores in order to evaluate quality of life (QOL) ( Table 4 ). All assessed indices were significantly lower than the national standard index (score=50), except for body pain (p=0.103). CES-D, AQ, and both state and trait anxiety of STAI, while CAARS scores were significantly negatively correlated with role physical, social functioning, general health, and mental health status. In contrast, IQ in the JART and WAIS-III were not correlated with any QOL parameters.
Genetic analysis and dystrophin isoform expression (Tables 5 and 6)
Deletion mutations (52, 68.4%), duplication mutations (3, 3.9%), small mutations (8, 10.5%), and others (no mutation by MLPA and not examined but diagnosed by immunohistochemistry, 13, 17.1%) were identified (Table 5) .
A total of 49 participants had deleterious Dp140 mutations. No significant differences were observed in developmental disorders, psychiatric disease, epilepsy, bullying, or problematic behavior between those with and without deleterious Dp140 expression modifiers (Supplementary table 2) .
Moreover, no significant differences in these parameters were observed between those with and without Dp71 deleterious mutations, except for problematic behavior (Supplementary table 2) .
DISCUSSION
This is a comprehensive report on various clinical aspects of central nervous system disorders associated with BMD, including developmental, intellectual, and psychological aspects, QOL, brain imaging, and disease background.
Of our study population, 21% had psychiatric diseases and 24% had mental problems. Schizophrenia (prevalence in Japan is 0.46% [9] ) and neurosis were more frequent in our participants than in the general population in Japan. While 32.5% of participants had depressive tendencies, as assessed by CES-D, only 2 were diagnosed with depression, suggesting the existence of a subclinical population of depressive BMD patients who require intervention. In addition, participants exhibited high state and trait anxiety. Environmental factors such as bullying and other social difficulties may influence the mental health of BMD patients. [5] These tendencies were not correlated with their intelligence or ambulation status, indicating that depressive and anxiety states were not secondary phenomena induced by mental retardation or/and physical disability.
In the present study, we report on brain atrophy in BMD patients that is unrelated to other complications such as embolism or trauma. Since not all patients with brain atrophy exhibit mental retardation or psychiatric diseases, we could not conclude that the atrophy is related to psychiatric or intellectual problems. Brain MRI of DMD patients has revealed lower total brain volume and lower grey matter volume, and subgroup analyses found that DMD_Dp140 (-) subjects contributed the most to grey matter volume differences and performed worse on information processing. [10] Currently, we cannot conclude that Dp140 expression is related to brain atrophy, as a very small proportion of our participants underwent brain MRI. More comprehensive studies using MRI imaging in conjunction to mental, developmental, and intellectual evaluations are underway. A prospective MRI study of BMD patients combined with intellectual and psychiatric evaluations is warranted.
Consistent with a previous report, evaluation of intelligence revealed the average IQ of BMD patients to be in the normal range.
[11] However, we found that JART scores were significantly higher than WAIS-III, especially in the PIQ. JART scores are the outcome of a standardized cognitive function test to estimate the premorbid IQ of examinees with cognitive impairments, indicating that intellectual disabilities are assumed to progress along with age. Based on the logistic regression model, JART scores significantly predicted the existence of psychiatric diseases, potentially indicating that IQ may be associated with the onset of psychiatric diseases. Therefore, these MRI findings indicate that BMD can cause progression in central nervous system disorders and may pose potential risks for psychiatric diseases.
Results of the intelligence test were not correlated with bullying, depressive states, anxiety, and QOL. On the other hand, depressive state and anxiety were significantly correlated with QOL scores, indicating the importance of mental health in maintaining the QOL of patients with BMD.
Mean QOL score of BMD patients was substantially lower than that of Japan's national standard. Within the items of the SF-36, general health, vitality, and mental health were significantly correlated with CES-D, AQ, CAARS, and STAI scores, highlighting the importance of appropriate approaches to address depressive and anxiety states and developmental disorders when aiming to improve the QOL of BMD patients.
In a previous study, we found that BMD is a potential risk factor for social difficulty and/or mental stress and psychiatric disease. [5] Similar to results from that study, nearly half of the BMD patients (45.6%) in the present study also suffered from bullying back when they were students. This suggests that bullying may affect the mental status of BMD patients.
Epilepsy in BMD has been described in some patient populations in Japan. Reportedly, 8% of patients with dysrrophinopathy experience epilepsy [12] . As for patients with DMD, the prevalence of epilepsy has been reported to be 7.9% according to a questionnaire survey [13] , or 6.3% based on medical records [14] . Our findings also suggested that some BMD patients are at risk of epilepsy, although the occurrence rate in the present study might have been underestimated due to study design (i.e., interview-based, no questions for parents) including mostly adult patients.
A significant difference was not detected in Dp140 or Dp71 expression based on most of the assessed parameters, including IQ, QOL, developmental disorders, problematic behavior, and psychiatric diseases. Therefore, unlike in patients with developmental disorders, problematic disorders, or epilepsy who had deleterious Dp140 or Dp71 mutations, we cannot conclude that differences in Dp140 or Dp71 expression caused the social issues. Only participants who had deleterious Dp140 mutations had developmental disorders, epilepsy, and problematic behavior, as well as more frequent psychiatric diseases and experiences being bullied, than those without deleterious mutations. Moreover, only problematic behavior was significantly correlated with deleterious mutations in Dp71, but not Dp140. While the significance is still unclear, these findings may reflect the causative nature of deleterious Dp140 or Dp71 mutations, which a larger sample size may help uncover.
This study has some limitations. First, the recruitment of participants from the NCNP Hospital is a potential source of selection bias, since the hospital has a specialized psychiatric department. However, the number of patients referred to our hospital due to psychiatric complications is not very high, and the hospital's psychiatrists are readily accessible to identify mental problems. Thus, we believe our study population is representative of the general BMD population. Second, some of the BMD patients at our hospital did not participate in the study, and some did not complete all psychological/psychiatric tests. Lack of time was the main reason for this.
Many patients only took tests they could complete in a short time frame (e.g., JART). It is also possible that patients with psychological or behavioral problems tended to participate in the study and/or the psychological tests, which would overestimate the prevalence of these problems. Third, 24 our study population was too small to reach a firm conclusion. In this regard, we are now collecting MRI data of dystrophinopathy patients to address questions relating to brain atrophy.
Notwithstanding these potential limitations, we believe this study is the first to address central nervous system issues of BMD.
In conclusion, BMD patients are at risk of bullying and psychiatric diseases. Parents, teachers, and supporters should be mindful of the daily environment of these patients and provide support to help them cope with stress. The CES-D found thirteen participants (32.5%) to be in a depressive state (>16), although only 2 had been diagnosed with depression. The STAI found that fifteen (38.5%) participants were in an anxious state (>44), and 20 (50%) had high trait anxiety (>44). Abnormalities of AQ (>33), CAARS index as self-reported and observer-reported (>66), and PARS for childhood and adolescence (>9) were 4 (11.4%), 8 (22.9%) and 3 (12.5%), and 3 (17.6%) and 0 (10.0%), respectively. Six participants had developmental disorders (mental retardation, pervasive developmental disorder), and nearly half suffered from bullying back when they were students; one with neurosis also had depression.
Fisher's exact test revealed that developmental disorders (p=0.04) and problematic behavior (p=0.05) were significantly (p=0.03) correlated with psychiatric diseases. The results of intelligence tests indicated that, on average, results were within the normal range.
JART scores were significantly higher than WAIS-III FIQ and PIQ scores, but not significantly higher than the WAIS-III VIQ scores. While 32.5% of participants had depressive tendencies, as assessed by CES-D, only two were diagnosed with depression, suggesting the existence of a subclinical population of depressive BMD patients who require intervention. Table 3 . Prevalence of disorders assessed by MINI.
Nineteen participants (46% of those assessed by MINI) met criteria for at least one lifetime MINI disorder. Ten participants reported having attempted suicide. Six participants were at one median risk, and 14 were at low risk. 
